A quality‐adjusted survival meta‐analysis of adjuvant chemotherapy for premenopausal breast cancer

Statistics in Medicine

Volumn 14, Issue 16, 1995, Pages 1771-1784

  Cole, Bernard F ^a   Gelber, Richard D ^b   Aron Goldhirsch, ^c  

^a BROWN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; MULTIVARIATE ANALYSIS; PREMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SYMPTOM; TIME; TOXICITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PREMENOPAUSE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029132075     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4780141606     Document Type: Article

References (27)

1. Systemtic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. Costs and benefits of adjuvant therapy in breast cancer: a quality‐adjusted survival analysis
3. Quality adjusted survival analysis
4. Quality‐of‐life‐adjusted evaluation of a randomized trial comparing adjuvant therapies for operable breast cancer
5. Nonparametric estimation from incomplete observations
6. A large sample study of the life table and product limit estimates under random censorship
7. A quality‐of‐life‐oriented endpoint for comparing therapies
8. Adjuvant CMF in breast cancer: comparative 5‐year results of 12 versus 6 cycles
9. Combination chemotherapy as an adjuvant treatment in operable breast cancer
10. The CMF program for operable breast cancer with positive axillary nodes
11. Multimodal treatment in operable breast cancer: five‐year results of the CMF programme
12. Ten‐year experience with CMF‐based adjuvant chemotherapy in resectable breast cancer
13. A controlled clinical trial of adjuvant chemotherapy in operable cancer of the breast
14. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer
15. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer
16. Adjuvant systemtic therapy in high‐risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients
17. Adjuvant chemotherapy and subsequent malignant disease
18. Adjuvant radiotherapy and chemotherapy in breast cancer
19. Adjuvant radiotherapy and chemotherapy in breast cancer
20. Influence of low‐dose adjuvant CMF chemotherapy on survival and locoregional recurrences in operable breast cancer
21. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer
22. A controlled trial of adujuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer
23. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node‐positive breast cancer: an update of the Guy's/Manchester trial
24. Current status of Milan adjuvant chemotherapy trials for node‐positive and node‐negative breast cancer
25. Adjuvant CMF in node‐negative and estrogen receptor negative breast cancer: updated results
26. Adjuvant hormonal chemotherapy in early breast cancer: early results from a controlled trial